Skip to main content

Advertisement

SpringerLink
Log in

An overview of vaccinations in HIV

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Prevention is an important aspect of HIV care in the era of highly active antiretroviral therapy. Vaccines provide an excellent opportunity to avert certain infectious diseases for which patients with HIV infection are at increased risk due to immunosuppression. However, the state of immunosuppression reduces the efficacy of vaccines and increases the risk associated with certain vaccines. The study of vaccine responses in patients with HIV infection has greatly advanced the understanding of the underlying immune deficits, particularly with regards to reduced CD4 cell number and function and the level of immune activation associated with chronic viremia. This research has also solidified the safety and utility of vaccines for this population. Continued research of vaccine responses will further our understanding of the immune system and optimize the utilization of routine immunizations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Campos M, Godson DL: The effectiveness and limitations of immune memory: understanding protective immune responses. International J Parasitol 2003, 33:655–661.

    Article  CAS  Google Scholar 

  2. Egea E, Iglesias A, Salazar M, et al.: The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991, 173:531–538.

    Article  PubMed  CAS  Google Scholar 

  3. Valdez H, Smith KY, Landay A, et al.: Response to immunization with recall and neonatigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11–21.

    Article  PubMed  CAS  Google Scholar 

  4. Lane HC, Masur H, Edgar LC, et al.: Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983, 309:453–458.

    Article  PubMed  CAS  Google Scholar 

  5. Glenney AT, Pope CG, Waddington H, et al.: XXIII-the antigenic value of toxoid precipitation by potassium alum. J Pathol Bacteriol 1926, 29:38–39.

    Google Scholar 

  6. Baylor NW, Egan W, Richman P: Aluminum salts in vaccines-US perspective. Vaccine 2002, 20:S18–23.

    Article  PubMed  CAS  Google Scholar 

  7. Chabalgoity JA, Baz A, Rial A, Grille S: The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 2007, 18:195–207.

    Article  PubMed  CAS  Google Scholar 

  8. Thio CL, Seaberg EC, Skolasky RJ, et al.: HIV-1, hepatitis B, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002, 360:1921–1926.

    Article  PubMed  Google Scholar 

  9. Laurence JC: Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005, 118(Suppl 10A):75S–83S.

    Article  PubMed  Google Scholar 

  10. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993, 42:1–18.

  11. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902–2908.

    Article  PubMed  CAS  Google Scholar 

  12. Overton ET, Sungkanuparph S, Powderly WG, et al.: Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045–1048.

    Article  PubMed  Google Scholar 

  13. Sasaki M, Foccacia R, deMessias-Reason IJ: Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545–4549.

    Article  PubMed  CAS  Google Scholar 

  14. Cooper CL, Davis HL, Angel JB, et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473–1479.

    Article  PubMed  CAS  Google Scholar 

  15. Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435–1441.

    Article  PubMed  CAS  Google Scholar 

  16. Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207–1213.

    Article  PubMed  Google Scholar 

  17. Overton ET, Nurutdinova D, Sungkanuparph S, et al.: Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007, 14:189–193.

    Article  PubMed  CAS  Google Scholar 

  18. Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290.

    Article  PubMed  CAS  Google Scholar 

  19. Lin JC, Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441–446.

    Article  PubMed  CAS  Google Scholar 

  20. Sullivan PS, Hanson DL, Dworkin MS, et al.: Adult and Adolescent Spectrum of HIV Disease Investigators. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000, 14:2781–2785.

    Article  PubMed  CAS  Google Scholar 

  21. Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430–433.

    PubMed  CAS  Google Scholar 

  22. Yamanaka H, Teruya K, Tanaka M, et al.: HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167–173.

    PubMed  CAS  Google Scholar 

  23. Fine AD, Bridges CB, De Guzman AM, et al.: Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001, 32:1784–1791.

    Article  PubMed  CAS  Google Scholar 

  24. Centers for Disease Control and Prevention: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1–24.

    Google Scholar 

  25. Klugman KP, Madhi SA, Feldman C: HIV and pneumococcal disease. Curr Opin Infect Dis 2007, 20:11–15.

    Article  PubMed  Google Scholar 

  26. Flannery B, Schrag S, Bennett NM, et al.: Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004, 291:2197–2203.

    Article  PubMed  CAS  Google Scholar 

  27. Gebo KA, Moore RD, Keruly JC, Chaisson RE: Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996, 173:857–862.

    PubMed  CAS  Google Scholar 

  28. Breiman RF, Keller DW, Phelan MA, et al.: Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633–2638.

    Article  PubMed  CAS  Google Scholar 

  29. Watera C, Nakiyingi J, Miiro G, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004, 18:1210–1213.

    Article  PubMed  Google Scholar 

  30. Feikin DR, Elie CM, Goetz MB, et al.: Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol 2004, 11:137–141.

    Article  PubMed  CAS  Google Scholar 

  31. Kroon FP, van Dissel JT, Ravensbergen E, et al.: Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999, 18:524–530.

    Article  PubMed  CAS  Google Scholar 

  32. Kurtzhals JA, Kjeldsen K, Heron I, Skinhoj P: Immunity against diphtheria and tetanus in human immunodeficiency virus-infected Danish men born 1950–1959. APMIS 1992, 100:803–808.

    Article  PubMed  CAS  Google Scholar 

  33. Chattopadhya D, Grover SS, Sharma M, et al.: Immune response in HIV-1-infected children with thalassaemia given a primary course of DPT vaccine before acquiring HIV-1 infection. Ann Trop Paediatr 2003, 23:279–292.

    Article  PubMed  CAS  Google Scholar 

  34. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222–1230.

    Article  PubMed  CAS  Google Scholar 

  35. Kroon FP, van Dissel JT, Labadie J, et al.: Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:1197–1203.

    PubMed  CAS  Google Scholar 

  36. Bonetti TC, Succi RC, Weckx LY, et al.: Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004, 22:3707–3712.

    Article  PubMed  CAS  Google Scholar 

  37. Stephens DS, Hajjeh RA, Baughman WS, et al.: Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995, 123:937–940.

    PubMed  CAS  Google Scholar 

  38. Kaplan LJ, Daum RS, Smaron M, McCarthy CA: Severe measles in immunocompromised patients. JAMA 1992, 267:1237–1241.

    Article  PubMed  CAS  Google Scholar 

  39. Wallace MR, Hooper DG, Graves SJ, Malone JL: Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994, 12:1222–1224.

    Article  PubMed  CAS  Google Scholar 

  40. Arpadi SM, Markowitz LE, Baughman AL, et al.: Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996, 97:653–657.

    PubMed  CAS  Google Scholar 

  41. Krasinski K, Borkowsky W: Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989, 261:2512–2516.

    Article  PubMed  CAS  Google Scholar 

  42. Kancherla VS, Hanson IC: Mumps resurgence in the United States. J Allergy Clin Immunol 2006, 118:938–941.

    Article  PubMed  Google Scholar 

  43. Madhi SA, Kuwanda L, Saarinen L, et al.: Immunogenicity and effectiveness of Haemophilus influenzae type B conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005, 23:5517–5525.

    Article  PubMed  CAS  Google Scholar 

  44. Oxman MN, Levin MJ, Johnson GR, et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271–2284.

    Article  PubMed  CAS  Google Scholar 

  45. Palefsky JM, Gillison ML, Strickler HD: Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006, 24(Suppl 3):S140–146.

    Article  PubMed  Google Scholar 

  46. Tasker SA, Schnepf GA, Lim M, et al.: Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 2004, 38:1320–1322.

    Article  PubMed  Google Scholar 

  47. Redfield RR, Wright DC, James WD, et al.: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987, 316:673–676.

    Article  PubMed  CAS  Google Scholar 

  48. Greenberg RN, Overton T, Haas DW, et al.: Safety and immunogenicity of Imvamune (MVA-BN) smallpox vaccine in HIV-infected subjects [abstract]. Paper presented at the 5th Annual ASM Biodefense and Emerging Disease Research Meeting. Washington, DC; February 27–March 2, 2007.

  49. Kroger AT, Atkinson WL, Marcuse EK, et al.: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1–48.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8011, St. Louis, MO, 63110, USA

    Edgar Turner Overton MD

Authors
  1. Edgar Turner Overton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edgar Turner Overton MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Overton, E.T. An overview of vaccinations in HIV. Curr HIV/AIDS Rep 4, 105–113 (2007). https://doi.org/10.1007/s11904-007-0016-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-007-0016-7

Keywords

Search

Navigation